Standard monoclonal antibodies bind one target. Bispecific antibodies bind two — and that single change opens up therapeutic ideas that simply weren't possible with monospecific drugs. Blinatumomab proved you could use an antibody to physically force a T cell to attack a cancer cell. Emicizumab showed you could use an antibody to mimic a missing clotting factor in hemophilia. Teclistamab and Mosunetuzumab brought the T-cell engager idea into new IgG-like formats with much friendlier dosing schedules.
This guide unpacks how bispecific antibodies work, the different molecular architectures, and the major drugs that have established the modality. You can explore them interactively in the Antibody Design Lab.
The basic idea: two binders, one molecule
A normal antibody has two identical Fab arms. They both bind the same epitope on the same target. A bispecific antibody has two different Fab arms (or two different scFv fragments) that bind different things. When the antibody is in the body, it can engage both targets simultaneously, which physically tethers them together.
For T-cell engagers, the two targets are a tumor antigen (CD19, BCMA, CD20, etc.) on one side and CD3 on the other side. CD3 is the universal T cell activation signal. By forcing CD3 to engage in close proximity to the tumor antigen, the bispecific antibody creates an artificial immunological synapse — and the T cell kills the bound cell, regardless of whether it would have normally recognized that cell on its own.
Crucially, this mechanism does not require the T cell to have a T cell receptor that matches the tumor antigen, and it does not require MHC presentation. Many tumors evade normal T cell immunity by downregulating MHC class I. Bispecific T-cell engagers bypass that escape mechanism completely.
Architectures of bispecifics
BiTE (Bispecific T-cell Engager)
The classic BiTE format pioneered by Micromet (now part of Amgen) is two single-chain Fv fragments connected by a short flexible linker. No Fc, no constant region. The molecule is small (~55 kDa) and very compact, which means it can squeeze into tight intercellular spaces but also that it gets cleared from the body very quickly. Blinatumomab is the canonical BiTE.
IgG-like bispecifics
Newer formats keep an IgG-like Fc region for long half-life and also for some effector functions (or specifically engineered to avoid them). The challenge is that you need to make sure the right heavy chain pairs with the right light chain — otherwise you get a mix of monospecific and bispecific products. Solutions include knobs-into-holes Fc engineering, common light chain designs, CrossMab, and DuoBody. Teclistamab and Mosunetuzumab use IgG-like architectures.
DART, TandAb, and other variants
Dozens of other bispecific formats exist: DART (dual-affinity re-targeting), TandAb (tandem diabody), kih-IgG, scFv-Fc-scFv, and more. Each makes different trade-offs between size, half-life, manufacturability, and binding geometry. The format you pick influences how the drug behaves in patients more than people usually appreciate.
Blinatumomab: the prototype T-cell engager
Blinatumomab (Blincyto) was approved by the FDA in 2014 for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL). It is a CD19 × CD3 BiTE. CD19 is expressed on essentially all B cells and B-ALL cells. CD3 is the universal T cell signaling complex. The two scFv arms are connected by a flexible glycine-serine linker.
When Blinatumomab is in the bloodstream of a patient with circulating B-ALL cells, it binds CD19 on the leukemia cells with one arm and CD3 on any nearby T cell with the other. The T cell is forcibly activated, the immunological synapse forms, and the T cell releases perforin and granzymes that kill the leukemia cell. The same T cell can then move on and kill another B-ALL cell that the same Blinatumomab molecule (or a different one) has tagged.
The continuous-infusion problem
Because Blinatumomab is small and lacks an Fc region, its plasma half-life is only about two hours. To maintain therapeutic levels in patients, it has to be given as a continuous intravenous infusion via a portable pump for cycles of four weeks at a time. That is a significant burden on patients and a strong motivation for the IgG-like bispecifics that came later.
Cytokine release syndrome
When you forcibly activate a lot of T cells against a lot of target cells, they release a flood of pro-inflammatory cytokines (IL-6, IFN-γ, TNF-α). The result is fever, hypotension, and sometimes severe systemic inflammation called cytokine release syndrome (CRS). CRS is managed with step-up dosing, supportive care, and the IL-6 receptor antibody Tocilizumab. Neurological side effects (ICANS) are also a known risk and require careful monitoring.
The BCMA wave: Teclistamab and friends
Multiple myeloma is a malignancy of plasma cells, which strongly express BCMA (B-cell maturation antigen, also called TNFRSF17). That makes BCMA an attractive bispecific target. Teclistamab (Tecvayli) is a BCMA × CD3 IgG-like bispecific antibody approved in 2022 for relapsed or refractory multiple myeloma.
Unlike Blinatumomab, Teclistamab uses a full-length IgG4 Fc with knobs-into-holes engineering to enforce correct heavy-chain pairing. The Fc gives it a half-life of around two weeks instead of two hours, so it can be dosed subcutaneously once a week rather than via a continuous pump. That is a quality-of-life revolution compared to BiTE-style dosing.
Other BCMA × CD3 bispecifics have followed (Elranatamab, Linvoseltamab), and the broader concept has been extended to GPRC5D (Talquetamab) and FcRH5, all in multiple myeloma. The space is moving fast.
Mosunetuzumab and CD20 × CD3
Mosunetuzumab (Lunsumio) is a CD20 × CD3 bispecific approved in 2022 for relapsed or refractory follicular lymphoma. CD20 is the same target as Rituximab, which has been the workhorse anti-CD20 antibody for two decades. The bispecific approach turns CD20 binding into a T cell-mediated killing mechanism rather than relying on ADCC and complement.
Glofitamab is another CD20 × CD3 bispecific with a different format (2:1 binding — two CD20 arms and one CD3 arm) that gives it stronger avidity for CD20-positive cells. It was approved in 2023 for diffuse large B-cell lymphoma. Both drugs are part of the broader story that bispecific T-cell engagers may eventually compete with CAR-T cell therapies on accessibility and cost.
Emicizumab: bispecifics outside oncology
Emicizumab (Hemlibra) is the most beautiful example of bispecific engineering applied to a non-oncology problem. Hemophilia A patients have non-functional or absent Factor VIII, a clotting cofactor that normally brings Factor IXa and Factor X together in the coagulation cascade.
Emicizumab is a humanized IgG4 bispecific antibody with one arm that binds Factor IXa and another arm that binds Factor X. When both factors are bound by the same Emicizumab molecule, they are held in close proximity and Factor IXa can activate Factor X — exactly what Factor VIII would do. The antibody is a functional replacement for the missing protein.
Emicizumab is given as a once-weekly or once-monthly subcutaneous injection and has dramatically reduced the bleeding burden of hemophilia A patients. It works even in patients who have developed inhibitor antibodies against recombinant Factor VIII, because Emicizumab's mechanism is structurally distinct.
Explore bispecifics in the Antibody Design Lab
The Antibody Design Lab includes pre-loaded workspaces for the major bispecifics:
- Blinatumomab — CD19 × CD3 BiTE for B-ALL
- Teclistamab — BCMA × CD3 IgG-like bispecific for multiple myeloma
- Emicizumab — Factor IXa × Factor X bispecific for hemophilia A
Bottom line
Bispecific antibodies turn the antibody scaffold from a simple binder into a programmable tether. Once you can attach two different binders to the same molecule, you can use the geometry of biology to do things that single-target antibodies never could: force T cells to attack cancer cells regardless of MHC, replace a missing clotting cofactor, bring a payload to a specific cell, or simultaneously block two pathways. The format and architecture choices matter enormously, and the field is still rapidly evolving toward better dosing, better safety, and broader indications.